Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lonza Group | London | Healthcare | Biotechnology & Medical Research | £33.26B | 72.6x | -1.39 | £467.05 | -8.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
arGEN X BV | London | Healthcare | Biotechnology & Medical Research | £23.69B | -153x | -3.06 | £396.19 | -1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Genmab | London | Healthcare | Biotechnology & Medical Research | £11.38B | 18.9x | 0.99 | £180.09 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Qiagen NV | London | Healthcare | Biotechnology & Medical Research | £7.54B | 138.7x | -1.87 | £33.88 | -6.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Zealand Pharma | London | Healthcare | Biotechnology & Medical Research | £6.48B | -69.1x | -2.25 | £91.50 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
BB Biotech L | London | Healthcare | Biotechnology & Medical Research | £1.77B | 8.6x | 0.02 | £32.28 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AddLife | London | Healthcare | Biotechnology & Medical Research | £1.42B | 162.8x | -2.38 | £11.63 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Genus | London | Healthcare | Biotechnology & Medical Research | £1.30B | 164.7x | -2 | £19.76 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 35.7% Upside | Upgrade to Pro+ | |
Oxford BioMedica | London | Healthcare | Biotechnology & Medical Research | £405.04M | -2.7x | 0.01 | £3.73 | -1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 25.2% Upside | Upgrade to Pro+ | |
PureTech Health | London | Healthcare | Biotechnology & Medical Research | £369.93M | -6.9x | 0.07 | £1.56 | 3.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Faron Pharmaceuticals Oy | London | Healthcare | Biotechnology & Medical Research | £224.94M | -5.6x | -1.45 | £2.15 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Allergy Therapeutics | London | Healthcare | Biotechnology & Medical Research | £223.55M | -1.6x | -0.14 | £0.05 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Bioventix | London | Healthcare | Biotechnology & Medical Research | £200.96M | 23.2x | 11.38 | £39 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Hvivo | London | Healthcare | Biotechnology & Medical Research | £196.22M | 11.1x | 0.02 | £0.29 | -0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 24.4% Upside | Upgrade to Pro+ | |
Corbus Pharmaceuticals Holdings | London | Healthcare | Biotechnology & Medical Research | £192.94M | -4.4x | -0.12 | £16.11 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Avacta Group | London | Healthcare | Biotechnology & Medical Research | £179.34M | -5.5x | -0.24 | £0.50 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
4BASEBIO UK SOCIETAS | London | Healthcare | Biotechnology & Medical Research | £177.99M | -25.1x | 0.48 | £13.90 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 28.6% Upside | Upgrade to Pro+ | |
Scancell | London | Healthcare | Biotechnology & Medical Research | £139.44M | -12.5x | -0.62 | £0.15 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Transgene | London | Healthcare | Biotechnology & Medical Research | £121.39M | -4.9x | -0.19 | £0.94 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Inovio Pharmaceuticals | London | Healthcare | Biotechnology & Medical Research | £106.64M | -1.1x | -0.04 | £4.09 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Futura | London | Healthcare | Biotechnology & Medical Research | £106.32M | -29.2x | -0.97 | £0.35 | 2.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Batm Advanced Comm | London | Healthcare | Biotechnology & Medical Research | £89.85M | -275.5x | 1.77 | £0.21 | -3.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Verastem | London | Healthcare | Biotechnology & Medical Research | £78.88M | -0.8x | -0.05 | £2.03 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Biotec Pharmacon | London | Healthcare | Biotechnology & Medical Research | £65.82M | 62.7x | 41.48 | £1.28 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Poolbeg Pharma | London | Healthcare | Biotechnology & Medical Research | £48M | -11.1x | -1.1 | £0.10 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novacyt SA | London | Healthcare | Biotechnology & Medical Research | £43.95M | -1.5x | 0.18 | £0.63 | 2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Shield Therapeutics | London | Healthcare | Biotechnology & Medical Research | £37.23M | -1.4x | -0.02 | £0.05 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
OncoCyte | London | Healthcare | Biotechnology & Medical Research | £34.73M | -0.8x | -0.02 | £2.27 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Relief Therapeutics Holding | London | Healthcare | Biotechnology & Medical Research | £30.05M | -0.7x | -0.01 | £2.38 | 67.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Incanthera | Aquis Exchange | Healthcare | Biotechnology & Medical Research | £29.22M | -12.2x | 0 | £0.25 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |